Cited by 2,561Schizophrenia research and treatmentMental Health and PsychiatryTreatment of Major Depression

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Leucht, Stefan, Cipriani, Andrea, Spineli, Loukia, Mavridis, Dimitris, Örey, Deniz, Richter, Franziska, Samara, Myrto, Barbui, Corrado, Engel, Rolf R, Geddes, John R, Kissling, Werner, Stapf, Marko Paul, Lässig, Bettina, Salanti, Georgia, Davis, John M·2013·The Lancet

DOI 10.1016/s0140-6736(13)60733-3

Open this paper in CoChat — free account

Abstract

Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.Findings We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.Funding None.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)60733-3

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Self-citation
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521

Show all 61 references

Research works printed but not linked: 1

Leucht, 2009, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia, Am J Psychiatry, 166, 152, 10.1176/appi.ajp.2008.08030368 · DOI

Sorted by citations

The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Self-citation
Schizophrenia
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Self-citation
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
Goodwin, G., Haddad, P. M., Ferrier, I. N., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, J. R., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,350
Self-citation
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Schizophrenia
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,163
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers
Clementz, B. A., Sweeney, J. A., Hamm, J. P., Ivleva, E. I., Ethridge, L. E., Pearlson, G. D., Keshavan, M. S., & Tamminga, C. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14091200 · Cited by 768
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citation
EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH)
Stubbs, B., Vancampfort, D., Hallgren, M., Firth, J., Veronese, N., Solmi, M., Brand, S., Cordes, J., Malchow, B., Gerber, M., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.07.004 · Cited by 697
Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Clozapine v . first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis
Siskind, D. J., McCartney, L., Goldschlager, R., & Kisely, S. R. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 646
Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
Haddad, P. M., Brain, C., & Scott, J. L. (2014) · Patient Related Outcome Measures · doi:10.2147/prom.s42735 · Cited by 617
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 615
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16121358 · Cited by 542
Self-citation
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Schizophrenia
Marder, S. R., & Cannon, T. D. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1808803 · Cited by 571
Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders
Pringsheim, T. M., Okun, M. S., Müller‐Vahl, K., Martino, D., Jankovic, J. J., Cavanna, A. E., Woods, D. W., Robinson, M., Jarvie, E., Roessner, V., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007466 · Cited by 532
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 560
Pharmaceuticals in freshwater aquatic environments: A comparison of the African and European challenge
Fekadu, S., Alemayehu, E., Dewil, R., & der Bruggen, B. V. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.11.072 · Cited by 525
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis
Riboh, J. C., Saltzman, B. M., Yanke, A. B., Fortier, L. A., & Cole, B. J. (2015) · The American Journal of Sports Medicine · doi:10.1177/0363546515580787 · Cited by 420
Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
Kaar, S. J., Natesan, S., McCutcheon, R. A., & Howes, O. D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 404
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Leucht, S., Samara, M. T., Heres, S., Patel, M. X., Woods, S. W., & Davis, J. M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu001 · Cited by 373
Self-citation
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S. S., Seneviratne, S., Suraweera, C. U., & de Silva, V. A. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 399
Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis
Miura, T., Noma, H., Furukawa, T. A., Mitsuyasu, H., Tanaka, S., Stockton, S., Salanti, G., Motomura, K., Shimano-Katsuki, S., Leucht, S., et al. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70314-1 · Cited by 364
Self-citation
Persecutory delusions: a cognitive perspective on understanding and treatment.
Freeman, D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00066-3 · Cited by 356
Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 376
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Brannan, S. K., Sawchak, S. T., Miller, A., Lieberman, J. A., Paul, S. M., & Breier, A. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2017015 · Cited by 343
Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study
Loebel, A. D., Cucchiaro, J. B., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. S. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070984 · Cited by 343
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
Kane, J. M., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.038 · Cited by 325
Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method
Leucht, S., Samara, M. T., Heres, S., Patel, M. X., Furukawa, T. A., Cipriani, A., Geddes, J. R., & Davis, J. M. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv037 · Cited by 334
Self-citation
Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma
Li, T., Lindsley, K. B., Rouse, B., Hong, H., Shi, Q., Friedman, D. S., Wormald, R., & Dickersin, K. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.005 · Cited by 323
Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics
Masuda, T., Misawa, F., Takase, M., Kane, J. M., & Correll, C. U. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1702 · Cited by 321
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives
Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N. G., & Sawa, A. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.016 · Cited by 337
Management of Delirium in Palliative Care: a Review
Grassi, L. G., Caraceni, A. T., Mitchell, A. J., Nanni, M. G., Berardi, M. A., Caruso, R., & Riba, M. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0550-8 · Cited by 302
Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301
Self-citation
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 305
Self-citation
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Koblan, K. S., KENT, J. M., Hopkins, S. C., Krystal, J. H., Cheng, H., GOLDMAN, R. S., & Loebel, A. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911772 · Cited by 311
Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070985 · Cited by 293
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
Maintenance treatment with antipsychotic drugs for schizophrenia
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 293
Self-citation
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
Correll, C. U., Davis, R. E., Weingart, M., Saillard, J., O’Gorman, C., Kane, J. M., Lieberman, J. A., Tamminga, C. A., Mates, S. L., & Vanover, K. E. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4379 · Cited by 289
International trends in antipsychotic use: A study in 16 countries, 2005–2014
Hálfdánarson, Ó., Zoëga, H., Aagaard, L., Bernardo, M., Brandt, L., Fusté, A. C., Furu, K., Garuolienè, K., Hoffmann, F., Huybrechts, K. F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.001 · Cited by 293
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Second‐generation antipsychotic effect on cognition in patients with schizophrenia—a meta‐analysis of randomized clinical trials
Nielsen, R. E., Levander, S. E., Telléus, G. K., Jensen, S. O. W., Christensen, T. Ø., & Leucht, S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12374 · Cited by 269
Self-citation
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Li, P., Snyder, G. L., & Vanover, K. E. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160608084834 · Cited by 279
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Haddad, P. M., & Correll, C. U. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318781475 · Cited by 259
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A. M., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., & Scarselli, M. (2021) · Pharmaceuticals · doi:10.3390/ph14030238 · Cited by 270
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial
Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250
Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial
Morrison, A. P., Turkington, D., Pyle, M., Spencer, H. M., Brabban, A., Dunn, G., Christodoulides, T., Dudley, R. E. J., Chapman, N., Callcott, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62246-1 · Cited by 265
Antipsychotics, mood stabilisers, and risk of violent crime
Fazel, S., Zetterqvist, J., Larsson, H., Långström, N., & Lichtenstein, P. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60379-2 · Cited by 261
Regional Heterogeneity in Gene Expression, Regulation, and Coherence in the Frontal Cortex and Hippocampus across Development and Schizophrenia
Collado‐Torres, L., Burke, E. E., Peterson, A., Shin, J. H., Straub, R. E., Rajpurohit, A., Semick, S. A., Ulrich, W. S., Price, A. J., Valencia, C., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.013 · Cited by 234
A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia
Jauhar, S., Nour, M. M., Veronese, M., Rogdaki, M., Bonoldi, I., Azis, M., Turkheimer, F., McGuire, P., Young, A. H., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2943 · Cited by 233
Clozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234
Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
Krause, M., Zhu, Y., Huhn, M., Schneider‐Thoma, J., Bighelli, I., Nikolakopoulou, A., & Leucht, S. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0869-3 · Cited by 234
Self-citation
Prevalence and predictors of treatment dropout from physical activity interventions in schizophrenia: a meta-analysis
Vancampfort, D., Rosenbaum, S., Schuch, F. B., Ward, P. B., Probst, M., & Stubbs, B. (2016) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.11.008 · Cited by 225
Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis
Curtis, J., Watkins, A., Rosenbaum, S., Teasdale, S., Kalucy, M., Samaras, K., & Ward, P. B. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12230 · Cited by 227
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
CASALE, A. D., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 243
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors
Sykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., & Charlton, S. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00716-z · Cited by 218
Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach
Koutsouleris, N., Kahn, R. S., Chekroud, A. M., Leucht, S., Falkai, P., Wobrock, T., Derks, E. M., Fleischhacker, W., & Hasan, A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30171-7 · Cited by 217
Self-citation
Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence
Correll, C. U., Rubio, J. M., Inczedy-Farkas, G., Birnbaum, M. L., Kane, J. M., & Leucht, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0624 · Cited by 214
Self-citation
Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
Carbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018) · World Psychiatry · doi:10.1002/wps.20579 · Cited by 214
Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
Sabé, M., Pillinger, T., Kaiser, S., Chen, C., Taipale, H. T., Tanskanen, A. J., Tiihonen, J., Leucht, S., Correll, C. U., & Solmi, M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104608 · Cited by 222
Self-citation
Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis
Furukawa, T. A., Salanti, G., Atkinson, L. Z., Leucht, S., Ruhe, H. G., Turner, E. H., Chaimani, A., Ogawa, Y., Takeshima, N., Hayasaka, Y., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010919 · Cited by 214
Self-citation
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain
Harvey, R. J., & Yee, B. K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3893 · Cited by 213
Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment
Sarpal, D. K., Argyelan, M., Robinson, D. G., Szeszko, P. R., Karlsgodt, K. H., John, M., Weissman, N., Gallego, J. A., Kane, J. M., Lencz, T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121571 · Cited by 212
Right care, first time: a highly personalised and measurement‐based care model to manage youth mental health
Hickie, I. B., Scott, E. M., Cross, S. P., Iorfino, F., Davenport, T. A., Guastella, A. J., Naismith, S. L., Carpenter, J. S., Rohleder, C., Crouse, J. J., et al. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50383 · Cited by 208
“First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects
Young, S. L., Taylor, M., & Lawrie, S. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114562090 · Cited by 212
Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness
Mazereel, V., Detraux, J., Vancampfort, D., van Winkel, R., & Binder, M. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573479 · Cited by 233
Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Carton, L., Cottencin, O., Lapeyre‐Mestre, M., Geoffroy, P. A., Favre, J., Simon, N., Bordet, R., & Rolland, B. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150619092903 · Cited by 208
Network meta-analyses should be the highest level of evidence in treatment guidelines
Leucht, S., Chaimani, A., Cipriani, A. S., Davis, J. M., Furukawa, T. A., & Salanti, G. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0715-4 · Cited by 202
Self-citation
European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment
Roessner, V., Eichele, H., Stern, J. S., Skov, L., Rizzo, R., Debes, N. M., Nagy, P., Cavanna, A. E., Termine, C., Ganos, C., et al. (2021) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-021-01899-z · Cited by 216
Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis
Milosavljevic, F., Bukvic, N., Pavlovic, Z., Miljevic, C., Pešic, V., Molden, E., Ingelman-Sundberg, M., Leucht, S., & Jukic, M. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3643 · Cited by 218
Self-citation
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 204
A primer on network meta-analysis with emphasis on mental health
Mavridis, D., Giannatsi, M., Cipriani, A., & Salanti, G. (2015) · Evidence Based Mental Health · doi:10.1136/eb-2015-102088 · Cited by 198
Self-citation
Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis
Zhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Giovane, C. D., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv060 · Cited by 199
QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update
Beach, S. R., Celano, C. M., Sugrue, A. M., Adams, C. N., Ackerman, M. J., Noseworthy, P. A., & Huffman, J. C. (2017) · Psychosomatics · doi:10.1016/j.psym.2017.10.009 · Cited by 210
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia
GOFF, D. C., Falkai, P., Fleischhacker, W. W., Girgis, R. R., Kahn, R. S., Uchida, H., Zhao, J., & Lieberman, J. A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091016 · Cited by 201
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
Kahn, R. S., Rossum, I. W.-V., Leucht, S., McGuire, P. K., Lewis, S. W., Leboyer, M., Arango, C., Dazzan, P., Drake, R., Heres, S., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30252-9 · Cited by 194
Self-citation
Antipsychotic Drugs and the Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death: A Nation-wide Case-Crossover Study
Wu, C., Tsai, Y., & Tsai, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001568 · Cited by 191
Weight gain and antipsychotics: a drug safety review
Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.974549 · Cited by 187
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Siafis, S., Tzachanis, D., Samara, M. T., & Papazisis, G. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170630163616 · Cited by 195
Self-citation
Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
Wagner, E. M., Siafis, S., Fernando, P., Falkai, P., Honer, W. G., Roeh, A., Siskind, D. J., Leucht, S., & Hasan, A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01613-2 · Cited by 206
Self-citation
Psychosis
Arciniegas, D. B. (2015) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000466662.89908.e7 · Cited by 202
Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia
Beck, K., Hindley, G., Borgan, F., Ginestet, C. E., McCutcheon, R. A., Brugger, S. P., Driesen, N. R., Ranganathan, M., D’Souza, D. C., Taylor, M. J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.4693 · Cited by 201
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
Correll, C. U., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101275 · Cited by 183
Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies
Hirsch, L., Yang, J. J., Bresee, L. C., Jetté, N., Patten, S. B., & Pringsheim, T. M. (2017) · Drug Safety · doi:10.1007/s40264-017-0543-0 · Cited by 182
Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity
Halder, N., & Lal, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660342 · Cited by 190
Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study
Jukić, M. M., Smith, R. L., Haslemo, T., Molden, E., & Ingelman‐Sundberg, M. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30088-4 · Cited by 181
Treatment-Resistant Schizophrenia
Elkis, H., & Buckley, P. F. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.01.006 · Cited by 194
Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications
Tek, C., Küçükgöncü, S., Gülöksüz, S., Woods, S. W., Srihari, V. H., & Annamalai, A. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12251 · Cited by 187
Clozapine as a Model for Antipsychotic Development
Nucifora, F. C., Mihaljevic, M. M., Lee, B. J., & Sawa, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0552-9 · Cited by 182

Authors: Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M.
Affiliations: TUM Klinikum (DE)
University of Verona (IT)
University of Ioannina (GR)
Ludwig-Maximilians-Universität München (DE)
Warneford Hospital (GB)
University of Illinois Chicago (US)
Corresponding author: Leucht, Stefan
ORCID: Leucht, Stefan
Cipriani, Andrea
Spineli, Loukia
Mavridis, Dimitris
Samara, Myrto
Barbui, Corrado
Engel, Rolf R
Geddes, John R
Salanti, Georgia
Davis, John M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2013-09
Volume: 382
Issue: 9896
Pages: 951-962
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)60733-3
OpenAlex: W2009832071
Cited by: 2,561
References: 61
Citations by year: 2026: 134 · 2025: 135 · 2024: 161 · 2023: 146 · 2022: 182 · 2021: 215 · 2020: 223 · 2019: 221 · 2018: 217 · 2017: 228 · 2016: 255 · 2015: 243 · 2014: 160 · 2013: 36
FWCI: 164.63
Type: journal article
Language: en
Open access: closed
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0611-10150)
H. Lundbeck A/S
Medical Research Council
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, drug efficacy comparison, tolerability, Bayesian framework, weight gain, extrapyramidal symptoms, QTc prolongation, sedation, clozapine, amisulpride, olanzapine, risperidone, paliperidone, zotepine
MeSH terms: Adult, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks